Seguir
William Dahut
William Dahut
National Cancer Institute
Email confirmado em mail.nih.gov
Título
Citado por
Citado por
Ano
Androgen deprivation therapy for prostate cancer
N Sharifi, JL Gulley, WL Dahut
Jama 294 (2), 238-244, 2005
12512005
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, ...
Journal of Clinical Oncology 28 (7), 1099, 2010
11832010
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
11401999
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis
X Zhu, S Wu, WL Dahut, CR Parikh
American Journal of Kidney Diseases 49 (2), 186-193, 2007
7762007
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
WL Dahut, JL Gulley, PM Arlen, Y Liu, KM Fedenko, SM Steinberg, ...
Journal of clinical oncology 22 (13), 2532-2539, 2004
4522004
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
JL Gulley, PM Arlen, A Bastian, S Morin, J Marte, P Beetham, KY Tsang, ...
Clinical Cancer Research 11 (9), 3353-3362, 2005
4242005
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
WD Figg, W Dahut, P Duray, M Hamilton, A Tompkins, SM Steinberg, ...
Clinical Cancer Research 7 (7), 1888-1893, 2001
4132001
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
RA Madan, M Mohebtash, PM Arlen, M Vergati, M Rauckhorst, ...
The lancet oncology 13 (5), 501-508, 2012
3602012
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
PM Arlen, JL Gulley, C Parker, L Skarupa, M Pazdur, D Panicali, ...
Clinical cancer research: an official journal of the American Association …, 2006
3432006
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
JL Gulley, PM Arlen, RA Madan, KY Tsang, MP Pazdur, L Skarupa, ...
Cancer Immunology, Immunotherapy 59, 663-674, 2010
3402010
Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke
DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ...
American journal of preventive medicine 20 (2), 16-66, 2001
3342001
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
ER Gardner, WL Dahut, CD Scripture, J Jones, JB Aragon-Ching, N Desai, ...
Clinical Cancer Research 14 (13), 4200-4205, 2008
2692008
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer
J Gulley, AP Chen, W Dahut, PM Arlen, A Bastian, SM Steinberg, K Tsang, ...
The Prostate 53 (2), 109-117, 2002
2682002
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
WD Stein, JL Gulley, J Schlom, RA Madan, W Dahut, WD Figg, Y Ning, ...
Clinical Cancer Research 17 (4), 907-917, 2011
2612011
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer
JL Marshall, N Rizvi, J Kauh, W Dahut, M Figuera, MH Kang, WD Figg, ...
Journal of Experimental Therapeutics and Oncology 2 (6), 325-332, 2002
2552002
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
JL Gulley, PM Arlen, KY Tsang, J Yokokawa, C Palena, DJ Poole, ...
Clinical Cancer Research 14 (10), 3060-3069, 2008
2472008
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
F Karzai, D VanderWeele, RA Madan, H Owens, LM Cordes, A Hankin, ...
Journal for immunotherapy of cancer 6, 1-12, 2018
2382018
Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer
A Hamada, T Sissung, DK Price, R Danesi, CH Chau, N Sharifi, D Venzon, ...
Clinical cancer research 14 (11), 3312-3318, 2008
2312008
The role of lineage plasticity in prostate cancer therapy resistance
H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ...
Clinical cancer research 25 (23), 6916-6924, 2019
2302019
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time
PM Arlen, F Bianco, WL Dahut, A D'Amico, WD Figg, SJ Freedland, ...
The Journal of urology 179 (6), 2181-2186, 2008
2272008
O sistema não pode efectuar a operação agora. Tente mais tarde.
Artigos 1–20